Press coverage about Versartis (NASDAQ:VSAR) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Versartis earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3254167117703 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Versartis (NASDAQ:VSAR) opened at $2.03 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.52 and a current ratio of 1.52. Versartis has a 12-month low of $1.60 and a 12-month high of $24.00.
Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same period last year, the business earned ($0.92) earnings per share. research analysts anticipate that Versartis will post -4.14 EPS for the current fiscal year.
VSAR has been the subject of several research reports. Cantor Fitzgerald set a $14.00 price objective on Versartis and gave the stock a “buy” rating in a research note on Friday, October 27th. Piper Jaffray Companies reissued a “buy” rating and set a $26.00 price objective on shares of Versartis in a research note on Friday, September 8th. ValuEngine raised Versartis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and set a $9.00 price objective (down from $28.00) on shares of Versartis in a research note on Friday, September 22nd. Finally, SunTrust Banks cut Versartis from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $4.00 in a research report on Friday, September 22nd. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $7.22.
In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the firm’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total value of $7,007,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 2,132,769 shares of company stock valued at $7,014,761. 10.90% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Versartis (VSAR) Share Price” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-versartis-vsar-share-price.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.